Weekly paclitaxel infusion in elderly patients with solid tumors

Tumori

Volumn 88, Issue SUPPL. 1, 2002, Pages

  Repetto, Lazzaro ^a   Pietropaolo, Maria ^a   Granata, Roberta ^a   Ventura, Irene ^a   Gianni, Walter ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; PACLITAXEL; RADIOSENSITIZING AGENT; TRASTUZUMAB;

AGED; AGING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MULTIMODALITY CANCER THERAPY; NEUROPATHY; SOLID TUMOR;

EID: 0036194013     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800112     Document Type: Conference Paper

References (6)

1. Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) +/- taxane (T) therapy
2. Multicenter Phase II Trial of weekly Paclitaxel in women with metastatic breast cancer
3. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer
4. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
5. Weekly paclitaxel in advanced non-small cell lung cancer
6. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube and peritoneum: A gynecologic oncology group study